Roots of Clinical Resistance to STI-571 Cancer Therapy

Christophe Barthe, Pascale Cony‐Makhoul, Junia V. Melo, J Mahon

Science · 2001 · 277 citations · 8 references

Concepts

Abstract

STI-571, a new Abl tyrosine kinase inhibitor recently approved by the Food and Drug Administration, is highly effective in treating the early stages of chronic myeloid leukemia (CML), but remissions induced in advanced phases tend to be relatively short-lived, an observation that suggests the

References

8